Supplemental Information

Convergent evolution of monocyte differentiation in adult skin instructs Langerhans cell identity

Anna Appios, James Davies, Sofia Sirvent, Stephen Henderson, Sébastien Trzebanski, Johannes Schroth, Morven L. Law, Inês Boal Carvalho, Marlene Magalhaes Pinto, Cyril Carvalho, Howard Yuan-Hao Kan, Shreya Lovlekar, Christina Major, Andres Vallejo, Nigel J. Hall, Michael Ardern-Jones, Zhaoyuan Liu, Florent Ginhoux, Sian M. Henson, Rebecca Gentek, Elaine Emmerson, Steffen Jung, Marta E. Polak and Clare L. Bennett.



Figure S1. scRNA-seq of monocyte-derived cells isolated from the epidermis 3 weeks post-BMT with T cells, related to Figure 1. A. Gating strategy for FACS isolation of donor and host CD11b⁺MHCII⁺ cells from murine GVHD epidermis for 10X scRNA-seq. **B.** Heatmap showing differentially expressed genes across clusters from dataset in figure 1B.



Figure S2. Analysis of scRNAseq data from epidermal myeloid cells, related to Figure 1. A. Parametric bootstrap showing single cell significance of hierarchical clustering identified in Figure 1B. **B.** UMAP and clustering of host LC (left) and heatmap overlays showing expression of indicated genes (right). **C.** Boxplot showing ratio of spliced to unspliced counts across indicated clusters. **D.** Heatmap showing the change in expression of indicated genes across pseudotime from monocyte to mLC differentiation.



Figure S3. Analysis of monocyte heterogeneity and differentiation to mLCs, related to **Figure 2. A.** Heatmap showing scaled expression of differentially expressed genes between monocyte sub-clusters. **B.** Representative FACS gating strategy for GMP, MDP and monocyte isolation (red gates) from murine bone marrow for subsequent culture. **C.** Representative flow plots showing GMP (left), MDP (middle) and monocytes (Mono, right) that were cultured for 6 days in the presence of GM-CSF, TGFβ and IL34. Gated on live, singlets, CD45⁺ cells. **D.** Bar graph showing the frequency of mLC-like cells (CD24⁺EpCAM⁺) as identified in (C). Data are represented as mean±SD (n=4 independent experiments). Statistical differences were assessed using a Friedman test, ** p<0.01. **E.** Representative flow plot showing host (CXCR4-tdTom^{neg}) and donor (CXCR4tdTom⁺) LC identified in murine epidermis following BMT+T cells using CXCR4-tdTom donor bone marrow. In these transplants all HSC-derived donor cells will be labelled with tdTom. **F.** Cells from (E) overlaid onto the LC-defining gating strategy to show separation of CD45⁺⁺ (mLC, donor) and CD45⁺⁺ (eLC, host) LC. **G.** Representative flow plots showing donor (left) and host (right) LC identified from murine epidermis following BMT+T cells using Ms4a3^{Cre/+}R26LSL-^{TdTomato}:Cx3cr1^{GFP/+} bone marrow.



Figure S4. Transcription factors associated with mLC differentiation, related to Figure 3. A. Heatmap showing scaled gene expression of transcription factors that are differentially expressed along the differentiation trajectory (Pseudotime) from monocyte to mig. mLC. B. Gating strategy and representative flow plots showing LC from WT and Ahr^{-/-} murine epidermis. C. Bar graph showing frequency of LC from WT and Ahr^{-/-} epidermis. Data are represented as mean±SD (n=3 for WT, 2 for Ahr^{-/-}). Statistical significance was assessed using a Mann-Whitney test. D. Gating strategy and representative flow plots showing mLC-like cells generated under indicated conditions. E. Diagram of experimental set up to track in vivo mLC differentiation following GVHD. Irradiated male B6 mice receive female ID2^{BFP} bone marrow, CD4 T cells with Matahari T cells and LC chimerism is assessed by flow cytometry 3 weeks later. F. Representative gating strategy used to track in vivo mLC differentiation using ID2^{BFP} reporter bone marrow.



Figure S5. scRNA-seq of keratinocytes from the GVHD epidermis, related to Figure 4. A. Gating strategy for FACS isolation of keratinocytes from the GVHD epidermis for 10X scRNA-seq. **B.** UMAP visualisation and clustering of keratinocytes from GVHD epidermis analysed by scRNAseq (left) and heatmap overlays showing expression of indicated genes across dataset (right). KC, keratinocytes. Expression scales: *Krt14* 0-6, *Krt5* 0-5, *Krt10* 0-6, *Krt79* 0-5, *Krt17* 0-6, *Mgst1* 0-5, *Mki67* 0-4, *Cdc20* 0-3. **C.** Heatmap overlay showing normalized expression of *Tgfb1* overlaid onto UMAP from figure 1B (CD11b⁺MHCII⁺ cells from GVHD epidermis). Expression scales: *Tgfb1* 0-3, *Itgb8* 0-2 **D.** Heatmap overlay showing normalized expression of *Itgb8* overlaid onto UMAP from (B). **E.** Representative flow plots showing EpCAM expression on hair follicle cells from untransplanted (Un-tx) and BMT+T epidermis. Gated on live, singlets, CD45^{neg}, Sca1^{neg} cells. **F.** Violin plots showing normalized expression of indicated genes across scRNA-seq clusters. Diff, differentiated. **G.** Bar graphs showing gMFI of Jag1 (left) and Jag2 (right) by EpCAM⁺ HF cells. Data are represented as

mean±SD (for Jag1, n=4 for Un-tx, n=8 for BMT+T cells. For Jag2, n=3 for each group). Statistical differences were assessed using a Mann-Whitney test.



Figure S6. Metabolic adaptation of resident mLC, related to Figure 5. A. Differential activity of metabolic reactions between MC and res. mLC (left) and Mrc1⁺ mac and res. mLC (right) analysed using COMPASS. Reactions (dots) are coloured by the sign of their Cohen's D statistic, bright dots P<0.05. **B.** Relationship between 8/10 of the most enriched res. mLC regulons identified by SCENIC (Regulon; left) and 9/10 of the res. mLC signature genes shown in Fig S1B (Target; right).



Figure S7. Bulk RNA-seq of *in vitro*-generated mLCs, related to Figure 5. A. Representative gating strategy for FACS isolation of CD11b^{int}EpCAM⁺ cells generated under conditions indicated in Figure 5C for bulk RNA-seq. B. Heatmap showing scaled expression of differentially expressed genes between the different indicated conditions.



Figure S8. Bulk RNA-seq of human LCs from newborns, infants and children, related to Figure 6. A. Gating strategy for cell sorting of human epidermis samples for LC bulk RNA-seq. **B**. Average TMM normalised gene expression levels in graphia clusters across newborns, infants and children. Data are analyzed using a Two-way ANOVA with Tukey's post-hoc test.

Antibody	Supplier	Catalog number	RRID	Dilution
Mouse				
Anti-mouse CD3e APC (145-2C11)	BioLegend	100312	AB 312677	1:200
Anti-mouse CD4 APC/Cy7 (GK1.5)	BioLegend	100414	AB 312699	1:200
Anti-mouse CD4 PE (GK1.5)	Thermo Fisher Scientific	12-0041-82	AB 465506	1:1000
Anti-mouse CD4 PE/Cy7 (GK1.5)	BioLegend	100422	AB 312706	1:200
Anti-mouse CD8a v450 (53-6.7)	BD Biosciences	560469	AB 1645281	1:100
Anti-mouse CD8a PE (53-6.7)	Thermo Fisher Scientific	12-0081-83	AB 465531	1:200
Anti-mouse CD11b e450 (M1/70)	Thermo Fisher Scientific	48-0112-82	AB 1582236	1:400
Anti-mouse CD11b APC (M1/70)	Thermo Fisher Scientific	17-0112-83	AB 469344	1:400
Anti-mouse CD11b PE (M1/70)	Thermo Fisher Scientific	12-0112-82	AB 2734869	1:400
Anti-mouse CD11c FITC (HL3)	BD Biosciences	553801	AB 395060	1:50
Anti-mouse CD11c APC (HL3)	BD Biosciences	550261	AB 398460	1:50
Anti-mouse CD16/32 PE-Cy7 (93)	BioLegend	101317	AB 2104156	1:200
Anti-mouse CD19 APC (1D3)	Thermo Fisher Scientific	17-0193-82	AB 1659676	1:200
Anti-mouse CD24 FITC (M1/69)	BioLegend	101805	AB 312839	1:500
Anti-mouse CD24 BV650 (M1/69)	BD Biosciences	563545	AB 2738271	1:500
Anti-mouse CD34 PE/Cy7 (SA376A4)	BioLegend	152217	AB 2910311	1:100
Anti-mouse CD34 BV421 (SA376A4)	BioLegend	152207	AB 2650766	1:100
Anti-mouse CD45 BV605 (30-F11)	BioLegend	103155	AB 2650656	1:200
Anti-mouse CD45.1 BV605 (A20)	BD Biosciences	563010	AB 2737948	1:200
Anti-mouse CD45.1 BV650 (A20)	BioLegend	110736	AB 11124743	1:200
Anti-mouse CD45.2 PerCP/Cv5.5 (104)	BD Biosciences	552950	AB 394528	1:200
Anti-mouse CD45.2 APC/Cv7 (104)	BioLegend	109824	AB 830788	1:200
Anti-mouse CD49b APC (DX5)	BioLegend	108910	AB 313416	1:200
Anti-mouse CD64 BV786 (X54-5/7.1)	BD Biosciences	741024	AB 2740644	1:100
Anti-mouse CD115 BV605 (AFS98)	BioLegend	135517	AB 2562760	1:100
Anti-mouse CD117 BV510 (2B8)	BioLegend	105839	AB 2629798	1:100
Anti-mouse CD135 PE (A2F10.1)	BioLegend	135306	AB 1877217	1:50
Anti-mouse CD206 BV711 (CO68C2)	BioLegend	141727	AB 2565822	1:100
Anti-mouse CD207 PE/Dazzle 594 (4C7)	BioLegend	144211	AB 2876491	1:200
Anti-mouse B220 BV786 (RA3-6B2)	BD Biosciences	563894	AB 2738472	1:500
Anti-mouse B220 APC (RA3-6B2)	BioLegend	103211	AB 312997	1:500
Anti-mouse EpCAM APC (G8.8)	Thermo Fisher Scientific	17-5791-82	AB 2716944	1:400
Anti-mouse EpCAM PerCP/e710 (G8.8)	Thermo Fisher Scientific	46-5791-82	AB 10598205	1:400
Anti-mouse Jagged-1 PE (HMJ1-29)	BioLegend	130907	AB 2561302	1:100
Anti-mouse Jagged-2 PE (HMJ2-1)	BioLegend	131007	AB 2128358	1:100
Anti-mouse Ly6C PE-Cy7 (AL-21)	BD Biosciences	560593	AB_1727557	1:200
Anti-mouse Ly6C FITC (AL-21)	BD Biosciences	553104	AB_394628	1:200
Anti-mouse Ly6G APC/Cy7 (1A8)	BioLegend	127624	AB_10640819	1:100
Anti-mouse Ly6G APC (1A8)	BioLegend	127613	AB_1877163	1:100
Anti-mouse MHCII BV510 (M5/114.15.2)	BioLegend	107636	AB_2561397	1:800
Anti-mouse MHCII APC/e780 (M5/114.15.2)	Thermo Fisher Scientific	47-5321-82	AB_1548783	1:800
Anti-mouse MHCII A700 (M5/114.15.2)	BioLegend	107621	AB 493727	1:400
Anti-mouse Sca-1 BV711 (D7)	BioLegend	108131	AB 2562241	1:100
Anti-mouse TER-119 APC (TER-119)	BioLegend	116212	AB 313713	1:200
Anti-mouse Vß8.3 TCR FITC (1B3.3)	BD Biosciences	553663	AB_394979	1:100
Anti-mouse Vß8.3 TCR PE (1B3.3)	BD Biosciences	553664	AB_394980	1:400
Human				
Anti-human CD207-PeVio700 (REA822)	Miltenyi Biotec	130-112-370	AB_2656213	1:100
Anti-human CD1a-VioBlue (REA736)	Miltenyi Biotec	130-111-875	AB_2889493	1:50
Anti human HLA-DR-VioGreen (REA805)	Miltenyi Biotec	130-111-795	AB 2652156	1:100

Table S1. List of flow cytometry antibodies used in this study.

Antibody	Supplier	Catalog number	RRID	Dilution
Anti-CD11b (M1/70)	Abcam	ab8878	AB_306831	1:200
Anti-MHCII (ER-TR3)	Abcam	ab15630	AB_302007	1:200
Anti-mouse I-A/I-E-488 (M5/114.15.2)	BioLegend	107615	AB_493524	1:200
Anti-mouse EpCAM-595 (G8.8)	BioLegend	118222	AB_2563322	1:400
Anti-KRT14 (polyclonal)	Convance	PRB-115P	AB_292096	1:500

 Table S2. List of primary antibodies used for confocal microscopy in this study.